SRF-373(Surface Oncology)

N/A

Report date: 2023/09/26 20:00:38

Base Information

Drug NameSRF-373(Surface Oncology)
Drug Alias NameAnti-CD73 MAb (Surface Oncology)SRF-373NZV-930
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of Action5'-nucleotidase inhibitorsImmunomodulatorsAntibody-dependent cell-mediated cytotoxicity (ADCC) effects +[4] 
Targets5'-nucleotidase
Therapy Area/IndicationsSolid tumoursProstatic Neoplasms, Castration-ResistantCarcinoma, Non-Small-Cell Lung +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSingapore +[10] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSurface Oncology Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovartis Pharma Ag
Active IndicationsN/A
Inactive IndicationsSolid tumoursProstatic Neoplasms, Castration-ResistantCarcinoma, Non-Small-Cell Lung +[8] 

Other Information

ATC CodeN/A
Related LinksN/A